Organogenesis to release FY2025 Q1 earnings on May 8 After-Market EST, forecast revenue USD 90.77 M, EPS USD -0.04

Brief Summary

Organogenesis is expected to report Q1 2025 revenue of $90.77 million and an EPS of -$0.04, compared to peers like Amazon whose revenue is anticipated between $151 billion and $155.5 billion and Apple with expected revenue of $94.06 billion and an EPS of $1.606 .

Impact of The News

Overview of Financial Indicators

• Revenue Expectations: Organogenesis is projected to post a revenue of $90.77 million for Q1 2025. This appears modest when juxtaposed against industry peers such as Amazon, which is forecasted to achieve revenue in the range of $151 billion to $155.5 billion , and Apple with anticipated revenue of $94.06 billion .
• EPS Expectations: The expected EPS for Organogenesis is -$0.04, suggesting the company is likely operating at a loss for the quarter. In contrast, Apple is expected to report an EPS of $1.606, indicating profitability .

Impact Analysis

• Market Expectations and Performance: With Organogenesis anticipated to report negative EPS, this financial briefing could potentially miss market expectations, especially if investors are comparing its performance against more profitable peers like Amazon and Apple.
• Business Status and Trends: The negative EPS points to potential operational challenges or cost inefficiencies within Organogenesis. This might raise concerns regarding the company’s financial health and its ability to sustain operations without incurring losses.
• Transmission Mechanisms: Investors might perceive this briefing as indicative of the company struggling to compete within its sector. The negative EPS could influence investor sentiment, possibly impacting stock price negatively in the short term, unless mitigated by strategic improvements or positive future guidance.